Company intelligence / Profile preview

Neuronostics

Bristol, England, United Kingdomneuronostics.com ↗

Ownership: Private
Development stage: Commercial

Overview

Neuronostics has developed BioEP™, a cloud-based decision support tool that uses mathematical modelling to analyze EEG data for digital biomarkers of epilepsy. The technology aims to increase diagnostic yield, enable faster and more accurate diagnoses, and improve patient outcomes. The company’s technology has won awards and is currently being trialled in clinical settings but does not yet have published pivotal clinical results or regulatory approvals.

Therapeutic areas: Neurology
Modalities: Device (digital biomarker platform)Non-pharmacological therapy (diagnostic/prognostic tool)Software as a Medical Device (SaMD)
Industry: Physiological Monitoring

Partnerships

Supported by Innovate UKNIHRacademic partnership with University of Exeterno major pharma/biotech partnerships disclosed

Beyond the preview

Go deeper on Neuronostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuronostics.

Explore the full profile